Tag: Obesity medication

As of September 2025, Retatrutide is not yet available for prescription and therefore does not have an official list price. However, based on the cost of comparable GLP-1 medications, the anticipated cash price for a month's supply of Retatrutide is estimated to be over $1,000 without insurance.

Investigational drug retatrutide has generated significant excitement in the medical community after showing participants lost up to 24% of their body weight in Phase 2 trials. However, this promising medication is not yet available in the USA, as it is still progressing through the necessary regulatory steps toward commercialization.

As of September 2025, Eli Lilly has not officially announced a price for its investigational oral weight loss and diabetes medication, orforglipron. With the average list price of current injectable GLP-1 drugs like Wegovy hovering around $1,300 per month, many anticipate orforglipron will be positioned to compete in the highly watched and expensive market for anti-obesity and diabetes treatments.

Eli Lilly holds multiple patents protecting Zepbound (tirzepatide), and the earliest potential date for a generic version's entry is estimated to be around 2036. However, the availability of a truly generic version may be delayed until 2039 due to other patents covering the drug's formulation and delivery device.

Clinical trials and manufacturer guidelines recommend beginning Wegovy at a specific initial dose to help the body adjust to the medication. This initial titration period is crucial, and the answer to 'Can I start Wegovy at 0.5 mg?' is typically no, for reasons related to patient tolerability and safety.

The FDA approved Qsymia for chronic (long-term) weight management in adults and adolescents aged 12 and older. However, the critical question, 'How long is it safe to be on Qsymia?', depends on sustained efficacy, tolerance to potential side effects, and consistent medical supervision.

According to anecdotal evidence from patients and medical experts, Contrave can be an effective treatment for quieting persistent and intrusive thoughts about food, commonly referred to as “food noise”. For individuals struggling with obsessive cravings and preoccupation with food, understanding how this medication works is crucial for successful weight management.

In a head-to-head clinical trial, tirzepatide (Zepbound) demonstrated superior average weight loss compared to semaglutide (Wegovy), achieving a 20.2% reduction versus 13.7% over 72 weeks. This breakthrough introduces a strong contender to the popular GLP-1 medication, leading many to ask, **What is the new weight loss drug better than Wegovy?**

As one of the most frequently prescribed weight-loss medications in the United States, phentermine is a powerful appetite suppressant used for the short-term treatment of obesity. This prescription drug is intended to be used as part of a comprehensive weight-reduction plan that includes a low-calorie diet and increased exercise.

According to the Food and Drug Administration, the brand name Didrex was discontinued in the U.S., but its generic equivalent, benzphetamine, remains available with a prescription. The diet pill Didrex is a sympathomimetic amine (stimulant) used for the short-term management of exogenous obesity.